导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.22% | 1102/4773 |
| 近一周 | 0.35% | 1000/5467 |
| 近一月 | -8.33% | 3830/5421 |
| 近一季 | -8.77% | 2796/5238 |
| 近半年 | 2.28% | 1178/4931 |
| 近一年 | 10.82% | 982/4400 |
| 近两年 | 98.75% | 634/2954 |
| 近三年 | 74.08% | 289/2253 |
| 成立以来 | 118.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.82% 1979/4961 |
27.91% 1019/5312 |
- - |
- - |
| 2025 | 46.96% 581/4813 |
2.05% 1480/3635 |
1.77% 2157/4076 |
42.53% 691/4524 |
-0.73% 2616/4813 |
| 2024 | 14.50% 1039/3463 |
-0.97% 1158/2808 |
-0.62% 800/3014 |
12.39% 2358/3129 |
3.52% 809/3463 |
| 2023 | -1.35% 506/2656 |
15.07% 221/2280 |
-0.16% 367/2385 |
-10.25% 1976/2515 |
-4.32% 962/2655 |
| 2022 | -24.64% 1237/2207 |
-17.09% 1178/1919 |
3.72% 1101/2016 |
-15.44% 1292/2113 |
3.64% 663/2208 |
| 2021 | 16.68% 261/1822 |
-3.87% 830/1255 |
14.43% 256/1330 |
-2.31% 564/1466 |
8.58% 148/1822 |
| 2020 | - - |
- - |
22.27% 213/1067 |
13.37% 324/1164 |
8.54% 670/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 华泰柏瑞中证科技ETF联接C VS. 长安沪深300非周期A(740101) |